Sionna Common Stock from 2010 to 2026

SION Stock   39.11  0.26  0.67%   
Sionna Therapeutics Common Stock yearly trend continues to be very stable with very little volatility. Common Stock is likely to drop to 3,300. During the period from 2010 to 2026, Sionna Therapeutics Common Stock quarterly data regression pattern had sample variance of 1.3 M and median of  2,000. View All Fundamentals
 
Common Stock  
First Reported
2010-12-31
Previous Quarter
5.8 K
Current Value
3.3 K
Quarterly Volatility
1.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sionna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sionna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 9.9 M, Interest Income of 9.9 M or Depreciation And Amortization of 503.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Sionna financial statements analysis is a perfect complement when working with Sionna Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Sionna Stock
Check out the analysis of Sionna Therapeutics Correlation against competitors.

Latest Sionna Therapeutics' Common Stock Growth Pattern

Below is the plot of the Common Stock of Sionna Therapeutics Common over the last few years. It is Sionna Therapeutics' Common Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sionna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock10 Years Trend
Slightly volatile
   Common Stock   
       Timeline  

Sionna Common Stock Regression Statistics

Arithmetic Mean2,474
Geometric Mean2,313
Coefficient Of Variation46.25
Mean Deviation779.93
Median2,000
Standard Deviation1,144
Sample Variance1.3M
Range3.8K
R-Value0.59
Mean Square Error908,029
R-Squared0.35
Significance0.01
Slope133.95
Total Sum of Squares20.9M

Sionna Common Stock History

2026 3300.0
2025 5750.0
2024 5000.0

Other Fundumenentals of Sionna Therapeutics

Sionna Therapeutics Common Stock component correlations

About Sionna Therapeutics Financial Statements

Sionna Therapeutics investors utilize fundamental indicators, such as Common Stock, to predict how Sionna Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Common Stock Shares Outstanding39.7 M35.3 M
Common Stock5.8 K3.3 K

Pair Trading with Sionna Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sionna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sionna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sionna Stock

  0.67DMAC DiaMedica TherapeuticsPairCorr

Moving against Sionna Stock

  0.74RAC Race OncologyPairCorr
  0.61AVH Avita MedicalPairCorr
  0.56VALN Valneva SE ADRPairCorr
  0.53DRMA Dermata TherapeuticsPairCorr
  0.34VANI Vivani MedicalPairCorr
The ability to find closely correlated positions to Sionna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sionna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sionna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sionna Therapeutics Common to buy it.
The correlation of Sionna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sionna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sionna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sionna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sionna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sionna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sionna Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sionna Therapeutics Common Stock:
Check out the analysis of Sionna Therapeutics Correlation against competitors.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sionna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.80)
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Sionna Therapeutics is measured differently than its book value, which is the value of Sionna that is recorded on the company's balance sheet. Investors also form their own opinion of Sionna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sionna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sionna Therapeutics' market value can be influenced by many factors that don't directly affect Sionna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sionna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.